Current status and perspectives in stem cell therapy for heart

Fen Chiung Lin, Wen Pin Chen, Pao Hsien Chu, Kou Gi Shyu, Ming Shien Wen

Research output: Contribution to journalReview articlepeer-review


Formost patients, the prognosis of heart failure remains poor despite therapeutic advancement in recent decades. The option of cardiac transplantation is high risk and limited by a shortage of donors. Traditionally, the heart had been considered a terminally differentiated organ incapable of regeneration. However, numerous preclinical and clinical studies have been performed since the first report of cell therapy in heart failure using skeletalmyoblasts in 2001. These investigations looked at the promising potential and use of several kinds of stem cells, which could some day dramatically alter the understanding of the regenerative capacity of the heart. To date, although there is no existing cardiac cell therapy that has been conclusively reported to be effective, stem cell-related cardiomyocyte regeneration strategies have become significant areas of research in modern cardiovascular medicine. In this review,we outline a variety of common cell sources, surface biomarkers of stem cells, and provide information related to cardiac cell therapy clinical trials.

Original languageEnglish
Pages (from-to)382-394
Number of pages13
JournalActa Cardiologica Sinica
Issue number5
Publication statusPublished - Sept 1 2014


  • Clinical trial
  • Stem cell

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Current status and perspectives in stem cell therapy for heart'. Together they form a unique fingerprint.

Cite this